Table 1.
Characteristics of the patients (n=16).
| Female sex, n (%) | 11 (69%) |
| Age, years, mean (range) | 58.4 (36.6-72.9) |
| Disease duration, years, mean (range) | 9.6 (0.5-48.0) |
| Rheumatoid factor positive, n (%) | 11 (69%) |
| CCP-antibody positive, n (%) | 12 (75%) |
| Erosive disease, n (%) | 7 (44%) |
| Disease activity (DAS28), n (%) | |
| Moderate | 13 (81%) |
| High | 3 (19%) |
| csDMARD regimen, n (%) | |
| Triple | 6 (37%) |
| Double | 7 (44%) |
| Single | 3 (19%) |
| Low-dose prednisolone, n (%) | 8 (50%) |
CCP, cyclic citrullinated peptide; DAS28, composite Disease Activity Score for 28 joints based on the C-reactive protein level (DAS28-4[CRP]); csDMARD, conventional systemic disease-modifying antirheumatic drug; n, number of patients.